Capsaicin 8% patch Qutenza and other current treatments for neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN)
- PMID: 33905384
- DOI: 10.1097/SPC.0000000000000545
Capsaicin 8% patch Qutenza and other current treatments for neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN)
Abstract
Purpose of review: Current oral treatments for neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) have limited clinical efficacy, and undesirable side-effects. Topically delivered treatments have the advantage of avoiding CNS side-effects, while relieving pain. We have reviewed treatments of neuropathic pain associated with CIPN, focusing on the Capsaicin 8% patch, which can provide pain relief for up to 3 months or longer after a single 30-60-min application.
Recent findings: Capsaicin 8% patch is a licensed treatment in the EU/UK for neuropathic pain and shown to be safe and effective in providing pain relief for patients with CIPN. Repeated daily oral or topical administrations are not required, as with other current treatments. The side-effects are transient and restricted to the time around patch application. New evidence suggests the Capsaicin 8% patch can promote the regeneration and restoration of skin nerve fibres in CIPN, in addition to the pain relief.
Summary: The Capsaicin 8% patch is now often a preferred a treatment option for localised neuropathic pain conditions, including the feet and hands in patients with CIPN. Capsaicin 8% patch can be repeated three-monthly, if needed, for a year. In addition to pain relief, it may have a disease-modifying effect.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification.J Pain Res. 2019 Jul 3;12:2039-2052. doi: 10.2147/JPR.S213912. eCollection 2019. J Pain Res. 2019. PMID: 31308732 Free PMC article.
-
Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series.J Oncol Pharm Pract. 2024 Jun;30(4):752-758. doi: 10.1177/10781552241230887. Epub 2024 Feb 28. J Oncol Pharm Pract. 2024. PMID: 38415287
-
Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain.Drugs. 2018 Sep;78(14):1489-1500. doi: 10.1007/s40265-018-0982-7. Drugs. 2018. PMID: 30251173 Review.
-
Topical treatment of chemotherapy-induced peripheral neuropathy (CIPN) with high-concentration (179 mg) capsaicin patch in breast cancer patients - results of the QUCIP study.Front Oncol. 2024 Sep 6;14:1452099. doi: 10.3389/fonc.2024.1452099. eCollection 2024. Front Oncol. 2024. PMID: 39309732 Free PMC article.
-
A critical review of the capsaicin 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults.Expert Rev Neurother. 2021 Mar;21(3):259-266. doi: 10.1080/14737175.2021.1874920. Epub 2021 Feb 4. Expert Rev Neurother. 2021. PMID: 33428495 Review.
Cited by
-
TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases.Signal Transduct Target Ther. 2023 Jul 5;8(1):261. doi: 10.1038/s41392-023-01464-x. Signal Transduct Target Ther. 2023. PMID: 37402746 Free PMC article. Review.
-
Vascular and nerve biomarkers in thigh skin biopsies differentiate painful from painless diabetic peripheral neuropathy.Front Pain Res (Lausanne). 2024 Oct 25;5:1485420. doi: 10.3389/fpain.2024.1485420. eCollection 2024. Front Pain Res (Lausanne). 2024. PMID: 39512388 Free PMC article.
-
Capsaicin: A Two-Decade Systematic Review of Global Research Output and Recent Advances Against Human Cancer.Front Oncol. 2022 Jul 13;12:908487. doi: 10.3389/fonc.2022.908487. eCollection 2022. Front Oncol. 2022. PMID: 35912207 Free PMC article.
-
Contributions of neuroimmune interactions to chemotherapy-induced peripheral neuropathy development and its prevention/therapy.Biochem Pharmacol. 2024 Apr;222:116070. doi: 10.1016/j.bcp.2024.116070. Epub 2024 Feb 20. Biochem Pharmacol. 2024. PMID: 38387528 Review.
-
Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy.Curr Treat Options Oncol. 2022 Jan;23(1):29-42. doi: 10.1007/s11864-021-00926-0. Epub 2022 Feb 15. Curr Treat Options Oncol. 2022. PMID: 35167004 Free PMC article. Review.
References
-
- Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007; 130 (Pt 4):1076–1088.
-
- Brouwers EEM, Huitema ADR, Boogerd W, et al. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol 2009; 48:832–841.
-
- Brydøy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009; 101:1682–1695.
-
- Strumberg D, Brügge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for nonseminomatous testicular cancer. Ann Oncol 2002; 13:229–236.
-
- Park SB, Lin CSY, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011; 16:708–716.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials